Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies

Tai, Yu-Hsiao; Tai, Yi‐Jou; Hsu, Hong–Yuan; Lee, Shu-Ping; Chen, Yun-Yuan; Chiang, Ying‐Cheng; Chen, Yuli; Chen, Chi-An; Cheng, Wen‐Fang

doi:10.3389/fphar.2017.00800

Cited by 14 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The risk factors for drug anaphylaxis are previous cardiovascular morbidity and older age, with BLs, anaesthetic agents and radiocontrast media (RCM) being the most common triggers . Regarding chemotherapeutic agents, data have shown that disease severity, histological type, malignant ascites, past drug allergies and cumulative dose can induce an earlier onset and be a risk of hypersensitivity reaction development …”

Section: Risk Factorsmentioning

confidence: 99%

“…In chemotherapy agents, essays to extend the infusion rates from one to two hours have been done to decrease the frequency of reactions with discrepant results …”

Section: Novel Tools For Managing Dhrmentioning

confidence: 99%

“…22 Regarding chemotherapeutic agents, data have shown that disease severity, histological type, malignant ascites, past drug allergies and cumulative dose can induce an earlier onset and be a risk of hypersensitivity reaction development. 23,24 White race, female, systemic mastocytosis and asthma have also shown to be a risk. 6,[25][26][27] Diabetes, chronic urticaria and drug allergies increase the risk of RCM reactions.…”

Section: Ris K Fac Tor Smentioning

confidence: 99%

“…172 In chemotherapy agents, essays to extend the infusion rates from one to two hours have been done to decrease the frequency of reactions with discrepant results. 23,173 Nowadays, desensitization is the only treatment for DHRs and is critical especially when patients need first-line therapy. 23,[174][175][176][177] This procedure allows the safe reintroduction of the drugs independently of the mechanisms.…”

Section: Novel Tool S For Manag Ing Dhrmentioning

confidence: 99%

“…23,173 Nowadays, desensitization is the only treatment for DHRs and is critical especially when patients need first-line therapy. 23,[174][175][176][177] This procedure allows the safe reintroduction of the drugs independently of the mechanisms. 178 New nondilution, or 1-solution, desensitization protocols are safe and effective for platinum agents' re-administration.…”

Section: Novel Tool S For Manag Ing Dhrmentioning

confidence: 99%

See 4 more Smart Citations

Recent developments and highlights in drug hypersensitivity

Mayorga

Fernandez

Montañez

et al. 2019

Allergy

View full text Add to dashboard Cite

Drug hypersensitivity reactions (DHRs) are nowadays the third cause of allergy after rhinitis and asthma with a significant increase in prevalence in both adults and paediatric population with new drugs included as culprit. For this, DHRs represent not only a health problem but also a significant financial burden for affected individuals and health systems. Mislabelling DHRs is showing to be a relevant problem for both, false label of drug allergic and false label of nonallergic. All this reinforces the need to improve accurate diagnostic approaches that allow an appropriate management.Moreover, there is a need for training both, nonallergist stakeholders and patients to improve the reaction identification and therefore decrease the mislabelling. The use of allergy cards has shown to be relevant to avoid the induction of DHRs due to the prescription of wrong medication.Recent developments over the last 2 years and highlights about risk factors, diagnostic approaches, mechanisms involved as well as prevention actions, and management have been reviewed. In these papers, it has been outlined the need for correct diagnosis and de-labelling of patients previously false-reported as allergic, which will improve the management and treatment of patients with DHRs. K E Y W O R D Sallergy diagnosis, allergy treatment, basic mechanisms, drug allergy, epidemiology | 2369

show abstract

Section: Risk Factorsmentioning

confidence: 99%

“…In chemotherapy agents, essays to extend the infusion rates from one to two hours have been done to decrease the frequency of reactions with discrepant results …”

Section: Novel Tools For Managing Dhrmentioning

confidence: 99%

Section: Ris K Fac Tor Smentioning

confidence: 99%

Section: Novel Tool S For Manag Ing Dhrmentioning

confidence: 99%

Section: Novel Tool S For Manag Ing Dhrmentioning

confidence: 99%

See 3 more Smart Citations

Recent developments and highlights in drug hypersensitivity

Mayorga

Fernandez

Montañez

et al. 2019

Allergy

View full text Add to dashboard Cite

show abstract

Platinum

Lansdown

2023

Patty's Toxicology

View full text Add to dashboard Cite

Platinum is ubiquitous in the human environment and is present in plants and animals, human food chains, airborne particles in inner‐city areas, and factory environments. It is a rare transitional metal with many uses in medicine, dentistry, and industrial applications. These include catalytic converters, electrical engineering, computers, space science, chemical syntheses, and jewelry. Platinum forms numerous durable alloys for clinical and industrial applications, and very many inorganic and organic compounds some of which are profound oxidizing agents and corrosive to skin and eyes. Others like the co‐ordination complexes, which are antimitotic through DNA binding, are potent anticancer drugs. The toxicity profile for platinum compounds is incomplete but permitted exposure levels (PEL) are shown for key materials. Respiratory distress, allergy, and hypersensitivity are principal hazards encountered through inhalation of airborne nanoparticles in mining, recycling, and emissions from vehicle exhaust systems. Metabolic pathways and excretion patterns involving liver and kidneys are discussed in relation to population studies. Urine analyses are clinical measures of platinum exposure. The anticancer/antimitotic drugs including cis ‐platin and carboplatin are clinically efficacious but cause nephrotoxicity, ear and sensi‐neural hearing, and possible carcinogenicity. Children are more sensitive. Experiments in animal models and cultured cells have contributed little in the understanding of hazards associated with platinum and related compounds. Whilst evidence of mutagenicity, DNA binding, clastogenicity is presented in standard laboratory screens, the 15th National Toxicology Program, Report on Carcinogens (2021) states that cis ‐platin should be reasonably anticipated to be a human carcinogen, despite no conclusive human epidemiological studies being available.

show abstract